Cevimeline for Sjögren's: Dry-Mouth Relief and Saliva Flow
Breath & MouthArticleThree placebo-controlled studies help distinguish reported comfort from measured saliva production, with a higher-dose comparison that adds a caution.

In this article
A six-week trial found patient-reported relief
A 75-person trial, funded by Snow Brand and Daiichi, compared cevimeline with placebo for six weeks; 61 people completed treatment. At the endpoint, 76% taking 30 mg three times daily reported improvement, versus 35% with placebo.1
“Improvement” meant rating overall dryness as better. It did not mean symptoms disappeared. The analysis used each participant’s last available post-dose assessment, which was not necessarily the six-week visit.1
Longer trials gave different symptom results
In a 12-week study of 197 patients, 30 mg three times daily improved overall dryness ratings compared with placebo. The 15 mg schedule did not, although both doses increased salivary flow.23
A separate 12-week study of 212 patients found no significant difference in overall symptom ratings between cevimeline and placebo. Yet 30 mg three times daily significantly increased saliva flow measured before and after a dose. A better flow measurement therefore did not consistently accompany a better patient rating.3
When discussing a prescription, name the problem you want to improve: needing water during meals, waking with dryness or discomfort while talking. Agree on a review date and record whether that particular problem changes. Those are discussion prompts, not outcomes established by every trial above.
A higher dose added sweating without clearer relief
In the six-week study, 60 mg three times daily did not produce significantly better overall dryness ratings than 30 mg. Sweating occurred in 67% at the higher dose, versus 16% at 30 mg. The higher schedule should not be read as a way to obtain greater relief.1
The U.S. indication covers dry-mouth symptoms in Sjögren’s syndrome. Uncontrolled asthma is a contraindication, and excessive sweating can cause dehydration. A prescriber must review suitability and interactions; our pilocarpine and cevimeline label guide covers additional cautions.3
Dental care continues when dryness feels better
Persistent dry mouth raises the risk of cavities and fungal infections. Keep up home oral care and regular dental check-ups, including discussion of cavity prevention. Feeling more comfortable does not tell you whether a tooth needs attention.4
The “Supporting Saliva” section of Is It My Breath? covers comfort measures and prescription saliva stimulants, including the need for clinician supervision.
These studies concern Sjögren's syndrome. Trial doses describe research, not instructions to start or change a prescription.
Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.
Sources
The research behind this article, in the order it’s cited. How we source our articles.
- Fife et al., Archives of Internal Medicine, 2002Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome: A Randomized Trial (opens in a new tab)abc
- Petrone et al., Arthritis & Rheumatism, 2002A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca (opens in a new tab)↩
- DailyMedCevimeline hydrochloride: prescribing information (opens in a new tab)abc
- National Institute of Dental and Craniofacial ResearchDry Mouth (opens in a new tab)↩
Spotted something out of date? Tell us and we’ll check it.


